 GAITHERSBURG, Md., Sept. 17, 2021 GLOBE NEWSWIRE -- MaxCyte, Inc., NASDAQ: MXCT; LSE: MXCT, MXCN, a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced that it is set to join the Russell 3000 and Russell 2000 indices, effective after the U.S. market opens on September 20, 2021, according to a preliminary list of quarterly IPO additions posted earlier this month by FTSE Russell. 